HIV / AIDS - Pipeline Review, H1 2016

  • ID: 3802768
  • Report
  • 886 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Abivax S.A.
  • Biotron Limited
  • Genticel S.A.
  • Medivir AB
  • PaxVax, Inc.
  • TeneoBio Inc
  • MORE
HIV / AIDS - Pipeline Review, H1 2016

Summary

‘HIV / AIDS - Pipeline Review, H1 2016’, provides an overview of the HIV / AIDS pipeline landscape.

The report provides comprehensive information on the therapeutics under development for HIV / AIDS, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for HIV / AIDS and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of HIV / AIDS
- The report reviews pipeline therapeutics for HIV / AIDS by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved HIV / AIDS therapeutics and enlists all their major and minor projects
- The report assesses HIV / AIDS therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for HIV / AIDS

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for HIV / AIDS
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding HIV / AIDS pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abivax S.A.
  • Biotron Limited
  • Genticel S.A.
  • Medivir AB
  • PaxVax, Inc.
  • TeneoBio Inc
  • MORE
Introduction

HIV / AIDS Overview

Therapeutics Development

HIV / AIDS - Therapeutics under Development by Companies

HIV / AIDS - Therapeutics under Investigation by Universities/Institutes

HIV / AIDS - Pipeline Products Glance

HIV / AIDS - Products under Development by Companies

HIV / AIDS - Products under Investigation by Universities/Institutes

HIV / AIDS - Companies Involved in Therapeutics Development

HIV / AIDS - Therapeutics Assessment

Drug Profiles

HIV / AIDS - Dormant Projects

HIV / AIDS - Discontinued Products

HIV / AIDS - Product Development Milestones

Appendix 843List of Tables

Number of Products under Development for HIV / AIDS, H1 2016

Number of Products under Development for HIV / AIDS - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Development by Companies, H1 2016 (Contd..4)

Number of Products under Development by Companies, H1 2016 (Contd..5)

Number of Products under Development by Companies, H1 2016 (Contd..6)

Number of Products under Development by Companies, H1 2016 (Contd..7)

Number of Products under Development by Companies, H1 2016 (Contd..8)

Number of Products under Development by Companies, H1 2016 (Contd..9)

Number of Products under Development by Companies, H1 2016 (Contd..10)

Number of Products under Investigation by Universities/Institutes, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..4)

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..5)

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Products under Development by Companies, H1 2016 (Contd..6)

Products under Development by Companies, H1 2016 (Contd..7)

Products under Development by Companies, H1 2016 (Contd..8)

Products under Development by Companies, H1 2016 (Contd..9)

Products under Development by Companies, H1 2016 (Contd..10)

Products under Development by Companies, H1 2016 (Contd..11)

Products under Development by Companies, H1 2016 (Contd..12)

Products under Development by Companies, H1 2016 (Contd..13)

Products under Development by Companies, H1 2016 (Contd..14)

Products under Development by Companies, H1 2016 (Contd..15)

Products under Development by Companies, H1 2016 (Contd..16)

Products under Development by Companies, H1 2016 (Contd..17)

Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..4)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..5)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..6)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..7)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..8)

HIV / AIDS - Pipeline by Abivax S.A., H1 2016

HIV / AIDS - Pipeline by AdAlta Pty Ltd., H1 2016

HIV / AIDS - Pipeline by Advanced Genetic Systems, Inc., H1 2016

HIV / AIDS - Pipeline by Akshaya Bio Inc., H1 2016

HIV / AIDS - Pipeline by AlbaJuna Therapeutics, H1 2016

HIV / AIDS - Pipeline by Altor BioScience Corporation, H1 2016

HIV / AIDS - Pipeline by Altravax, Inc., H1 2016

HIV / AIDS - Pipeline by Amarna Therapeutics B.V., H1 2016

HIV / AIDS - Pipeline by American Gene Technologies International Inc., H1 2016

HIV / AIDS - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2016

HIV / AIDS - Pipeline by Amunix Operating Inc. , H1 2016

HIV / AIDS - Pipeline by Antigen Express, Inc., H1 2016

HIV / AIDS - Pipeline by Aphios Corporation, H1 2016

HIV / AIDS - Pipeline by Apotex Inc., H1 2016

HIV / AIDS - Pipeline by Argos Therapeutics, Inc., H1 2016

HIV / AIDS - Pipeline by Arno Therapeutics, Inc., H1 2016

HIV / AIDS - Pipeline by Avexa Limited, H1 2016

HIV / AIDS - Pipeline by BCI Pharma, H1 2016

HIV / AIDS - Pipeline by BioClonetics Immunotherapeutics, Inc., H1 2016

HIV / AIDS - Pipeline by Bionor Pharma ASA, H1 2016

HIV / AIDS - Pipeline by Biosantech SA, H1 2016

HIV / AIDS - Pipeline by Biotron Limited, H1 2016

HIV / AIDS - Pipeline by Boehringer Ingelheim GmbH, H1 2016

HIV / AIDS - Pipeline by C4X Discovery Holdings PLC, H1 2016

HIV / AIDS - Pipeline by CEL-SCI Corporation, H1 2016

HIV / AIDS - Pipeline by Celgene Corporation, H1 2016

HIV / AIDS - Pipeline by Celldex Therapeutics, Inc., H1 2016

HIV / AIDS - Pipeline by Chipscreen Biosciences Ltd, H1 2016

HIV / AIDS - Pipeline by CompleGen, Inc., H1 2016

HIV / AIDS - Pipeline by ContraVir Pharmaceuticals, Inc., H1 2016

HIV / AIDS - Pipeline by Critical Outcome Technologies Inc., H1 2016

HIV / AIDS - Pipeline by CureVac GmbH, H1 2016

HIV / AIDS - Pipeline by Cytodyn Inc., H1 2016

HIV / AIDS - Pipeline by Enzo Biochem, Inc., H1 2016

HIV / AIDS - Pipeline by EpiVax, Inc., H1 2016

HIV / AIDS - Pipeline by eTheRNA Immunotherapies NV, H1 2016

HIV / AIDS - Pipeline by Etubics Corporation, H1 2016

HIV / AIDS - Pipeline by Evofem, Inc., H1 2016

HIV / AIDS - Pipeline by FIT Biotech Oy, H1 2016

HIV / AIDS - Pipeline by Formune S.L., H1 2016

HIV / AIDS - Pipeline by Fountain Biopharma Inc., H1 2016

HIV / AIDS - Pipeline by Frontier Biotechnologies Co., Ltd, H1 2016

HIV / AIDS - Pipeline by GeneCure LLC, H1 2016

HIV / AIDS - Pipeline by Genetic Immunity, Inc, H1 2016

HIV / AIDS - Pipeline by Genticel S.A., H1 2016

HIV / AIDS - Pipeline by GeoVax Labs, Inc., H1 2016

HIV / AIDS - Pipeline by Gilead Sciences, Inc., H1 2016

HIV / AIDS - Pipeline by GlaxoSmithKline Plc, H1 2016

HIV / AIDS - Pipeline by Globeimmune, Inc., H1 2016

HIV / AIDS - Pipeline by H-Phar S.A., H1 2016

HIV / AIDS - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2016

HIV / AIDS - Pipeline by Heat Biologics, Inc., H1 2016

HIV / AIDS - Pipeline by iCo Therapeutics Inc., H1 2016

HIV / AIDS - Pipeline by ID Pharma Co., Ltd., H1 2016

HIV / AIDS - Pipeline by Immune Response BioPharma, Inc., H1 2016

HIV / AIDS - Pipeline by Immunocore Limited, H1 2016

HIV / AIDS - Pipeline by ImQuest Life Sciences, H1 2016

HIV / AIDS - Pipeline by InnaVirVax SA, H1 2016

HIV / AIDS - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016

HIV / AIDS - Pipeline by Japan Tobacco Inc., H1 2016

HIV / AIDS - Pipeline by Johnson & Johnson, H1 2016

HIV / AIDS - Pipeline by Karyopharm Therapeutics, Inc., H1 2016

HIV / AIDS - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016

HIV / AIDS - Pipeline by Longevity Biotech, Inc, H1 2016

HIV / AIDS - Pipeline by MacroGenics, Inc., H1 2016

HIV / AIDS - Pipeline by Medestea Research & Production S.p.A., H1 2016

HIV / AIDS - Pipeline by Medivir AB, H1 2016

HIV / AIDS - Pipeline by Merck & Co., Inc., H1 2016

HIV / AIDS - Pipeline by Mologen AG, H1 2016

HIV / AIDS - Pipeline by Mymetics Corporation, H1 2016

HIV / AIDS - Pipeline by Myrexis, Inc., H1 2016

HIV / AIDS - Pipeline by NanoBio Corporation, H1 2016

HIV / AIDS - Pipeline by NanoViricides, Inc., H1 2016

HIV / AIDS - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016

HIV / AIDS - Pipeline by NeED Pharma s.r.l., H1 2016

HIV / AIDS - Pipeline by New World Laboratories, Inc., H1 2016

HIV / AIDS - Pipeline by Novartis AG, H1 2016

HIV / AIDS - Pipeline by Omeros Corporation, H1 2016

HIV / AIDS - Pipeline by Oncolys BioPharma Inc., H1 2016

HIV / AIDS - Pipeline by OncoNOx ApS, H1 2016

HIV / AIDS - Pipeline by Oncovir, Inc., H1 2016

HIV / AIDS - Pipeline by Orbis Biosciences, Inc., H1 2016

HIV / AIDS - Pipeline by Osel, Inc., H1 2016

HIV / AIDS - Pipeline by OyaGen Inc., H1 2016

HIV / AIDS - Pipeline by PaxVax, Inc., H1 2016

HIV / AIDS - Pipeline by Pepscan Therapeutics, H1 2016

HIV / AIDS - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2016

HIV / AIDS - Pipeline by Pfizer Inc., H1 2016

HIV / AIDS - Pipeline by Pharis Biotec GmbH, H1 2016

HIV / AIDS - Pipeline by Pharmsynthez, H1 2016

HIV / AIDS - Pipeline by Phoenix Biotechnology, Inc., H1 2016

HIV / AIDS - Pipeline by Polymun Scientific Immunbiologische Forschung GmbH, H1 2016

HIV / AIDS - Pipeline by Presidio Pharmaceuticals, Inc., H1 2016

HIV / AIDS - Pipeline by Profectus BioSciences, Inc., H1 2016

HIV / AIDS - Pipeline by ReceptoPharm, Inc., H1 2016

HIV / AIDS - Pipeline by Rodos BioTarget GmbH, H1 2016

HIV / AIDS - Pipeline by Sangamo BioSciences, Inc., H1 2016

HIV / AIDS - Pipeline by Sanofi, H1 2016

HIV / AIDS - Pipeline by Sanofi Pasteur SA, H1 2016

HIV / AIDS - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016

HIV / AIDS - Pipeline by SEEK Group, H1 2016

HIV / AIDS - Pipeline by Serometrix, LLC, H1 2016

HIV / AIDS - Pipeline by Sirenas Marine Discovery LLC, H1 2016

HIV / AIDS - Pipeline by Spider Biotech, H1 2016

HIV / AIDS - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016

HIV / AIDS - Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H1 2016

HIV / AIDS - Pipeline by Starpharma Holdings Limited, H1 2016

HIV / AIDS - Pipeline by Susavion Biosciences, Inc., H1 2016

HIV / AIDS - Pipeline by Taiga Biotechnologies, Inc., H1 2016

HIV / AIDS - Pipeline by TaiMed Biologics Inc., H1 2016

HIV / AIDS - Pipeline by Takara Bio Inc., H1 2016

HIV / AIDS - Pipeline by TechnoVax, Inc., H1 2016

HIV / AIDS - Pipeline by TeneoBio Inc, H1 2016

HIV / AIDS - Pipeline by TetraLogic Pharmaceuticals, H1 2016

HIV / AIDS - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016

HIV / AIDS - Pipeline by TGV-Laboratories, H1 2016

HIV / AIDS - Pipeline by Theraclone Sciences, Inc., H1 2016

HIV / AIDS - Pipeline by Theravectys SA, H1 2016

HIV / AIDS - Pipeline by Tobira Therapeutics, Inc., H1 2016

HIV / AIDS - Pipeline by Tomegavax, Inc., H1 2016

HIV / AIDS - Pipeline by Transgene Biotek Limited, H1 2016

HIV / AIDS - Pipeline by TVAX Biomedical, Inc., H1 2016

HIV / AIDS - Pipeline by United Biomedical, Inc., H1 2016

HIV / AIDS - Pipeline by United Therapeutics Corporation, H1 2016

HIV / AIDS - Pipeline by Vaccibody AS, H1 2016

HIV / AIDS - Pipeline by Vault Pharma Inc., H1 2016

HIV / AIDS - Pipeline by VDA Pharma, Inc., H1 2016

HIV / AIDS - Pipeline by VG Life Sciences, Inc., H1 2016

HIV / AIDS - Pipeline by Vichem Chemie Research Ltd., H1 2016

HIV / AIDS - Pipeline by ViiV Healthcare Limited, H1 2016

HIV / AIDS - Pipeline by Viriom Ltd., H1 2016

HIV / AIDS - Pipeline by ViroStatics srl, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

HIV / AIDS - Dormant Projects, H1 2016

HIV / AIDS - Dormant Projects (Contd..1), H1 2016

HIV / AIDS - Dormant Projects (Contd..2), H1 2016

HIV / AIDS - Dormant Projects (Contd..3), H1 2016

HIV / AIDS - Dormant Projects (Contd..4), H1 2016

HIV / AIDS - Dormant Projects (Contd..5), H1 2016

HIV / AIDS - Dormant Projects (Contd..6), H1 2016

HIV / AIDS - Dormant Projects (Contd..7), H1 2016

HIV / AIDS - Dormant Projects (Contd..8), H1 2016

HIV / AIDS - Dormant Projects (Contd..9), H1 2016

HIV / AIDS - Dormant Projects (Contd..10), H1 2016

HIV / AIDS - Dormant Projects (Contd..11), H1 2016

HIV / AIDS - Dormant Projects (Contd..12), H1 2016

HIV / AIDS - Dormant Projects (Contd..13), H1 2016

HIV / AIDS - Dormant Projects (Contd..14), H1 2016

HIV / AIDS - Dormant Projects (Contd..15), H1 2016

HIV / AIDS - Dormant Projects (Contd..16), H1 2016

HIV / AIDS - Dormant Projects (Contd..17), H1 2016

HIV / AIDS - Dormant Projects (Contd..18), H1 2016

HIV / AIDS - Dormant Projects (Contd..19), H1 2016

HIV / AIDS - Dormant Projects (Contd..20), H1 2016

HIV / AIDS - Dormant Projects (Contd..21), H1 2016

HIV / AIDS - Dormant Projects (Contd..22), H1 2016

HIV / AIDS - Dormant Projects (Contd..23), H1 2016

HIV / AIDS - Dormant Projects (Contd..24), H1 2016

HIV / AIDS - Dormant Projects (Contd..25), H1 2016

HIV / AIDS - Dormant Projects (Contd..26), H1 2016

HIV / AIDS - Dormant Projects (Contd..27), H1 2016

HIV / AIDS - Dormant Projects (Contd..28), H1 2016

HIV / AIDS - Dormant Projects (Contd..29), H1 2016

HIV / AIDS - Dormant Projects (Contd..30), H1 2016

HIV / AIDS - Dormant Projects (Contd..31), H1 2016

HIV / AIDS - Dormant Projects (Contd..32), H1 2016

HIV / AIDS - Dormant Projects (Contd..33), H1 2016

HIV / AIDS - Dormant Projects (Contd..34), H1 2016

HIV / AIDS - Dormant Projects (Contd..35), H1 2016

HIV / AIDS - Dormant Projects (Contd..36), H1 2016

HIV / AIDS - Dormant Projects (Contd..37), H1 2016

HIV / AIDS - Dormant Projects (Contd..38), H1 2016

HIV / AIDS - Dormant Projects (Contd..39), H1 2016

HIV / AIDS - Dormant Projects (Contd..40), H1 2016

HIV / AIDS - Dormant Projects (Contd..41), H1 2016

HIV / AIDS - Dormant Projects (Contd..42), H1 2016

HIV / AIDS - Dormant Projects (Contd..43), H1 2016

HIV / AIDS - Dormant Projects (Contd..44), H1 2016

HIV / AIDS - Discontinued Products, H1 2016

HIV / AIDS - Discontinued Products (Contd..1), H1 2016

HIV / AIDS - Discontinued Products (Contd..2), H1 2016

HIV / AIDS - Discontinued Products (Contd..3), H1 2016

HIV / AIDS - Discontinued Products (Contd..4), H1 2016

HIV / AIDS - Discontinued Products (Contd..5), H1 2016

HIV / AIDS - Discontinued Products (Contd..6), H1 2016 872List of Figures

Number of Products under Development for HIV / AIDS, H1 2016

Number of Products under Development for HIV / AIDS - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Top 10 Routes of Administration, H1 2016

Number of Products by Stage and Top 10 Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Abivax S.A.
AdAlta Pty Ltd.
Advanced Genetic Systems, Inc.
Akshaya Bio Inc.
AlbaJuna Therapeutics
Altor BioScience Corporation
Altravax, Inc.
Amarna Therapeutics B.V.
American Gene Technologies International Inc.
Amplyx Pharmaceuticals, Inc.
Amunix Operating Inc.
Antigen Express, Inc.
Aphios Corporation
Apotex Inc.
Argos Therapeutics, Inc.
Arno Therapeutics, Inc.
Avexa Limited
BCI Pharma
BioClonetics Immunotherapeutics, Inc.
Bionor Pharma ASA
Biosantech SA
Biotron Limited
Boehringer Ingelheim GmbH
C4X Discovery Holdings PLC
CEL-SCI Corporation
Celgene Corporation
Celldex Therapeutics, Inc.
Chipscreen Biosciences Ltd
CompleGen, Inc.
ContraVir Pharmaceuticals, Inc.
Critical Outcome Technologies Inc.
CureVac GmbH
Cytodyn Inc.
Enzo Biochem, Inc.
EpiVax, Inc.
eTheRNA Immunotherapies NV
Etubics Corporation
Evofem, Inc.
FIT Biotech Oy
Formune S.L.
Fountain Biopharma Inc.
Frontier Biotechnologies Co., Ltd
GeneCure LLC
Genetic Immunity, Inc
Genticel S.A.
GeoVax Labs, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Globeimmune, Inc.
H-Phar S.A.
Hadasit Medical Research Services & Development Ltd
Heat Biologics, Inc.
iCo Therapeutics Inc.
ID Pharma Co., Ltd.
Immune Response BioPharma, Inc.
Immunocore Limited
ImQuest Life Sciences
InnaVirVax SA
Inovio Pharmaceuticals, Inc.
Japan Tobacco Inc.
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Laboratorios Del Dr. Esteve S.A.
Longevity Biotech, Inc
MacroGenics, Inc.
Medestea Research & Production S.p.A.
Medivir AB
Merck & Co., Inc.
Mologen AG
Mymetics Corporation
Myrexis, Inc.
NanoBio Corporation
NanoViricides, Inc.
Navigen Pharmaceuticals, Inc.
NeED Pharma s.r.l.
New World Laboratories, Inc.
Novartis AG
Omeros Corporation
Oncolys BioPharma Inc.
OncoNOx ApS
Oncovir, Inc.
Orbis Biosciences, Inc.
Osel, Inc.
OyaGen Inc.
PaxVax, Inc.
Pepscan Therapeutics
Peregrine Pharmaceuticals, Inc.
Pfizer Inc.
Pharis Biotec GmbH
Pharmsynthez
Phoenix Biotechnology, Inc.
Polymun Scientific Immunbiologische Forschung GmbH
Presidio Pharmaceuticals, Inc.
Profectus BioSciences, Inc.
ReceptoPharm, Inc.
Rodos BioTarget GmbH
Sangamo BioSciences, Inc.
Sanofi
Sanofi Pasteur SA
Savoy Pharmaceuticals, Inc.
SEEK Group
Serometrix, LLC
Sirenas Marine Discovery LLC
Spider Biotech
Spring Bank Pharmaceuticals, Inc.
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Starpharma Holdings Limited
Susavion Biosciences, Inc.
Taiga Biotechnologies, Inc.
TaiMed Biologics Inc.
Takara Bio Inc.
TechnoVax, Inc.
TeneoBio Inc
TetraLogic Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
TGV-Laboratories
Theraclone Sciences, Inc.
Theravectys SA
Tobira Therapeutics, Inc.
Tomegavax, Inc.
Transgene Biotek Limited
TVAX Biomedical, Inc.
United Biomedical, Inc.
United Therapeutics Corporation
Vaccibody AS
Vault Pharma Inc.
VDA Pharma, Inc.
VG Life Sciences, Inc.
Vichem Chemie Research Ltd.
ViiV Healthcare Limited
Viriom Ltd.
ViroStatics srl
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll